NASDAQ:MACK Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis → Bill Gates is all about this tiny $2 stock (From Timothy Sykes) (Ad) Free MACK Stock Alerts $15.13 0.00 (0.00%) (As of 05/17/2024 04:00 PM ET) Add Compare Share Share Today's Range$15.13▼$15.1750-Day Range$14.65▼$15.1352-Week Range$11.53▼$15.89Volume1.26 million shsAverage Volume171,217 shsMarket Capitalization$223.77 millionP/E Ratio1.09Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Ad Timothy SykesBill Gates is all about this tiny $2 stockWhat does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthless $2 stock…>>Click here to discover why Bill Gates is all about this tiny $2 stock. About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More MACK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MACK Stock News HeadlinesMay 16, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024May 15, 2024 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Cut to "Sell" at StockNews.comMay 10, 2024 | marketwatch.comMerrimack Pharmaceuticals Shareholders OK Dissolution PlanMay 10, 2024 | businesswire.comMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockMay 10, 2024 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Pass Above Two Hundred Day Moving Average of $13.75May 9, 2024 | msn.comMerrimack Pharmaceuticals intends to declare $15.10 dividendMay 9, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 30, 2024 | businesswire.comMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 20, 2024 | seekingalpha.comMACK Merrimack Pharmaceuticals, Inc.April 3, 2024 | finance.yahoo.comDiagonal starts up with $128M to make better ‘activator’ antibody drugsMarch 27, 2024 | businesswire.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 8, 2024 | msn.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 7, 2024 | businesswire.comMerrimack Reports Full Year 2023 Financial ResultsMarch 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyFebruary 22, 2024 | benzinga.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putFebruary 15, 2024 | markets.businessinsider.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 13, 2024 | msn.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)See More Headlines Company Calendar Last Earnings5/15/2024Dividend Payable5/17/2024Today5/20/2024Ex-Dividend for 5/17 Dividend5/20/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MACK CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-720-8606Fax617-491-1386Employees426Year Founded2000Profitability EPS (Most Recent Fiscal Year)$13.87 Trailing P/E Ratio1.09 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1.93% Return on Assets-1.78% Debt Debt-to-Equity RatioN/A Current Ratio10.78 Quick Ratio10.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book11.55Miscellaneous Outstanding Shares14,790,000Free Float10,267,000Market Cap$223.77 million OptionableOptionable Beta1.45 Social Links Key ExecutivesMr. Gary L. Crocker M.B.A. (Age 72)President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Comp: $76kDr. Ulrik B. Nielsen Ph.D. (Age 52)Co-Founder & Independent Director Comp: $72.5kDr. Anthony J. Sinskey Ph.D. (Age 84)Sc.D., Co-Founder and Scientific Advisor Comp: $4.25kMr. Timothy R. Surgenor (Age 64)Secretary Key CompetitorsEmergent BioSolutionsNYSE:EBSRigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDARegulus TherapeuticsNASDAQ:RGLSView All CompetitorsInsiders & InstitutionsAristides Capital LLCBought 10,000 shares on 5/15/2024Ownership: 0.069%Vanguard Group Inc.Bought 11,893 shares on 5/10/2024Ownership: 4.272%BNP Paribas Financial MarketsBought 2,043 shares on 5/1/2024Ownership: 0.035%Eric AndersenBought 857 shares on 12/28/2023Total: $11,440.95 ($13.35/share)Eric AndersenBought 48,693 shares on 12/26/2023Total: $640,312.95 ($13.15/share)View All Insider TransactionsView All Institutional Transactions MACK Stock Analysis - Frequently Asked Questions How have MACK shares performed in 2024? Merrimack Pharmaceuticals' stock was trading at $13.41 on January 1st, 2024. Since then, MACK stock has increased by 12.8% and is now trading at $15.13. View the best growth stocks for 2024 here. When is Merrimack Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our MACK earnings forecast. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter. How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals? Merrimack Pharmaceuticals declared a dividend on Thursday, May 16th. Shareholders of record on Tuesday, May 21st will be paid a dividend of $15.10 per share on Friday, May 17th. This represents a dividend yield of 99.87%. The ex-dividend date of this dividend is Monday, May 20th. This is an increase from the stock's previous dividend of $1.50. Read our dividend analysis for MACK. When did Merrimack Pharmaceuticals' stock split? Merrimack Pharmaceuticals's stock reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM). Who are Merrimack Pharmaceuticals' major shareholders? Merrimack Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.27%), Aristides Capital LLC (0.07%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen. View institutional ownership trends. How do I buy shares of Merrimack Pharmaceuticals? Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MACK) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold4 Cryptos BETTER than BitcoinTrue Market InsidersDoes this make you sick?Allegiance GoldBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist My Default Watchlist Adding Merrimack Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
